Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Headache, Malaise, Myalgia
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild muscle pain and no interference with activity; Moderate fever (101.3 to 102 °F); Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild fatigue and no interference with activity; Headache and no interference with activity; Mild injection site redness; Mild injection site swelling; Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement); This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), PYREXIA (Moderate fever (101.3 to 102 °F)), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), PYREXIA (Moderate fever (101.3 to 102 °F)), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), FATIGUE (Mild fatigue and no interference with activity), HEADACHE (Headache and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), PYREXIA (Moderate fever (101.3 to 102 °F)), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), FATIGUE (Mild fatigue and no interference with activity), HEADACHE (Headache and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 101.3 to 102 °F, Moderate fever..     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.      Subject ID was mentioned as 67914-69924 Concomitant medication was not provided. During the 2 days after your COVID-19 vaccination, i.e., 20-Dec-2023 and 21-Dec-2023, patient experienced moderate injection site pain interfering with activity, moderate injection site tenderness (tenderness with movement), mild injection site redness, mild injection site swelling, moderate fever, mild fatigue and no interference with activity, mild malaise/feeling sick and no interference with activity, mild muscle pain and no interference with activity, mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting and headache and no interference with activity. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Master case